Effect of Ursodeoxycholic Acid on the Biodistribution and Excretion of Technetium-99m Radiopharmaceuticals in Rat: A Potential Image Quality Enhancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to investigate the effect of ursodeoxycholic acid (UDCA) on the biodistribution and excretion of technetium-99m (Tc-99m)-labeled radiopharmaceuticals. Materials and Methods: Tc-99m hydroxy-methylene-diphosphonate (HDP), Tc-99m pertechnetate, and Tc-99m dimercaptosuccinicacid (DMSA) were injected via the tail vein of rats. After 30 min, the control group was administered saline, and the UDCAgroup was given UDCA orally. Scintigraphy images were acquired after 30 min and 1, 2, 3, and 4 h. Radioactivity and rate of changewere compared. Tc-99m mercaptoacetyltriglycine (MAG3) imaging was also performed. Results: In image analysis of Tc-99m HDP, radioactivity of the buttock was lower in the UDCA group at 4 h. Rates of change in thebuttock were significantly different at 3 h–30 min and 4 h–30 min, and buttock radioactivity in the UDCA group had decreasedmore. In analysis of Tc-99m pertechnetate, radioactivity of the buttock was higher in the control group. Rates of change in the thyroidgland and buttock were different at 1 h–30 min, 3 h–30 min, and 4 h–30 min, with radioactivity in the UDCA group decreasingmore. In the analysis of Tc-99m DMSA, while the radioactivity of the kidneys in the control group showed little decrease at 1 h–30min, that in the UDCA group increased. In the analysis of Tc-99m MAG3 images, radioactivity and radioactivity/total body radioactivity(TBA) values for the kidneys were higher in the UDCA group at 2 min. At 5 and 10 min, radioactivity/TBA values for soft tissuein the UDCA group were lower than those in the control group. Conclusion: This study demonstrated that administration of UDCA increases renal excretion and soft tissue clearance of radiopharmaceuticals. This investigation could contribute to the broadening of applications of UDCA.
Abstract
Purpose: This study aimed to investigate the effect of ursodeoxycholic acid (UDCA) on the biodistribution and excretion of technetium-99m (Tc-99m)-labeled radiopharmaceuticals. Materials and Methods: Tc-99m hydroxy-methylene-diphosphonate (HDP), Tc-99m pertechnetate, and Tc-99m dimercaptosuccinicacid (DMSA) were injected via the tail vein of rats. After 30 min, the control group was administered saline, and the UDCAgroup was given UDCA orally. Scintigraphy images were acquired after 30 min and 1, 2, 3, and 4 h. Radioactivity and rate of changewere compared. Tc-99m mercaptoacetyltriglycine (MAG3) imaging was also performed. Results: In image analysis of Tc-99m HDP, radioactivity of the buttock was lower in the UDCA group at 4 h. Rates of change in thebuttock were significantly different at 3 h–30 min and 4 h–30 min, and buttock radioactivity in the UDCA group had decreasedmore. In analysis of Tc-99m pertechnetate, radioactivity of the buttock was higher in the control group. Rates of change in the thyroidgland and buttock were different at 1 h–30 min, 3 h–30 min, and 4 h–30 min, with radioactivity in the UDCA group decreasingmore. In the analysis of Tc-99m DMSA, while the radioactivity of the kidneys in the control group showed little decrease at 1 h–30min, that in the UDCA group increased. In the analysis of Tc-99m MAG3 images, radioactivity and radioactivity/total body radioactivity(TBA) values for the kidneys were higher in the UDCA group at 2 min. At 5 and 10 min, radioactivity/TBA values for soft tissuein the UDCA group were lower than those in the control group. Conclusion: This study demonstrated that administration of UDCA increases renal excretion and soft tissue clearance of radiopharmaceuticals. This investigation could contribute to the broadening of applications of UDCA.
참고문헌 (21)
- Hofmann AF, "Pharmacology of ursodeoxycholic acid, an enterohepatic drug", Scand J Gastroenterol Suppl, 204, pp.1~15 (1994)
- Angulo P, "Use of ursodeoxycholic acid in patients with liver disease", Curr Gastroenterol Rep, 4, pp.37~44 (2002)
- Van de Meeberg PC, "Therapy with ursodeoxycholic acid in cholestatic liver disease", Scand J Gastroenterol Suppl, 200, pp.15~20 (1993)
- Arrese M, "Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration", Biochem Pharmacol, 50, pp.1223~1232 (1995)
- Bowlus CL, "Primary biliary cholangitis : medical and specialty pharmacy management update", J Manag Care Spec Pharm, 22(10-a-s Suppl), pp.S3~15 (2016)
- 정환정, "Pretreatment with Ursodeoxycholic Acid (UDCA) as a Novel Pharmacological Intervention in Hepatobiliary Scintigraphy", Yonsei Medical Journal, 46(3), pp.394~398 (2005), 연세대학교의과대학
- Alam MS, "The role of ursodeoxycholic acid on growth performance and digestive enzyme activities of tilapia Oreochromis niloticus and kuruma prawn Marsupenaeus japonicus", Asian Fisheries Science Journal, 14, pp.441~451 (2001)
- Fluoro-D-Glucose by Milk and Ursodeoxycholic Acid in Preclinical Study, "Nuclear Medicine and Molecular Imaging", 2020, 105~113, pp.대한핵의학회, https:
- Nair AB, "A simple practice guide for dose conversion between animals and human", J Basic Clin Pharm, 7, pp.27~31 (2016)
- Bachrach WH, "Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part I", Dig Dis Sci, 27, pp.737~761 (1982)
- Roma MG, "Ursodeoxycholic acid in cholestasis : linking action mechanisms to therapeutic applications", Clin Sci (Lond), 121, pp.523~544 (2011)
- Leuschner U, "Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study", Dig Dis Sci, 30, pp.642~649 (1985)
- Kotb MA, "Molecular mechanisms of ursodeoxycholic acid toxicity & side effects : ursodeoxycholic acid freezes regeneration & induces hibernation mode", Int J Mol Sci, 13, pp.8882~8914 (2012)
- Schiedermaier P, "Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. A double-blind, cross-over, placebo-controlled study in healthy volunteers", Digestion, 61, pp.107~112 (2000)
- Saksena S, "Ursodeoxycholic acid in the treatment of liver diseases", Postgrad Med J, 73, pp.75~80 (1997)
- Franken PR, "Distribution and dynamics of(99m)Tc-pertechnetate uptake in the thyroid and other organs assessed by singlephoton emission computed tomography in living mice", Thyroid, 20, pp.519~526 (2010)
- Hingorani M, "The biology of the sodium iodide symporter and its potential for targeted gene delivery", Curr Cancer Drug Targets, 10, pp.242~267 (2010)
- Piepsz A, "Guidelines for 99mTc-DMSA scintigraphy in children", Eur J Nucl Med, 28, pp.BP37~BP41 (2001)
- Biassoni L, "Imaging in urinary tract infections : current strategies and new trends", Semin Nucl Med, 38, pp.56~66 (2008)
- Rossleigh MA, "Renal infection and vesico-ureteric reflux", Semin Nucl Med, 37, pp.261~268 (2007)
- Melis M, "Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy", J Nucl Med, 51, pp.1962~1968 (2010)